SKYN® 2022 SURVEY TAKES A LENS TO SEXUAL STIGMAS IN THE DIGITAL AGE
Annual Study from Sexual Wellness Leader Unveils Latest Purchasing Habits & Attitudes Toward Sex Toys
ISELIN, N.J., Oct. 25, 2022 /PRNewswire/ -- Leading sexual wellness brand, SKYN®, announces today the results of its annual study, designed to uncover the behaviors, attitudes and preferences of sexually active Gen Z and Millennials across the US. With the global sex toy market expected to grow to ~$25.53 billion by 2026, the 2022 SKYN® Sex & Intimacy Survey investigates modern perception and engagement within this booming category. The survey findings provide insight into the ways in which digital media, in particular, is shaping consumer outlook and purchasing trends.
As part of the brand's dedication to challenging traditional views of intimacy and helping consumers explore pleasure in new ways, the SKYN® Sex & Intimacy Survey sheds light on the current state of device usage, contemporary nuances of product education, and the relation of both to shifting stigmas.
Personal massagers are becoming de-stigmatized, but there is still some hesitation to disclose usage publicly:
Usage of personal massagers often starts in late adolescence, with age 20 being the average age for first use.
Exploration of the category continues, with 85% of respondents reporting the purchase of at least one new massager in just the last year.
Nearly one-third of respondents (31%) reported they would be uncomfortable with others knowing that they use personal massagers.
Most respondents (85%) feel they are able to determine if a personal massager aligns with their sexual orientation just by looking at it.
The majority of respondents (84%) shared they are comfortable with seeing personal massager visuals in stores.
Social media has a strong impact on perception and use of personal massagers:
Over half (55%) of Gen Zers were likely to be motivated to purchase a personal massager as a result of social media content, as compared to only 43% of Millennials.
Social media is influencing what we do in bed. 81% of respondents report that they are likely to implement tips provided through social media into their sex lives.
City-dwellers are more likely to post about use of personal massagers, with half of these respondents noting they would feel comfortable doing so compared to 41% of those in suburbs and 39% in rural areas.
For many, social media is a safe space for the discussion of personal massagers, with 32% engaging in these conversations via DM and 29% in public comments sections.
Personal massager content resonates best when it comes from everyday people, with 43% of all respondents noting this type of content is likely to inspire purchase. By contrast, only 38% noted the same for content created by influencers.
Purchasing habits are evolving as personal massagers grow in popularity and usage:
The vast majority of respondents (90%) are likely to purchase a personal massager online instead of in-store.
On average, respondents purchased 4 personal massagers in the past year, regardless of income or education level.
Over half of respondents (57%) would purchase a personal massager as a gift for someone else.
Gender impacts the types of toys people are buying, with over half (61%) of respondents sharing that they only purchase personal massagers specifically targeted towards their gender.
"The SKYN® brand is rooted in the pursuit of better intimacy. We aim to be the companion for all aspects of the journey to pleasure and a fundamental part of this is our deep understanding of that consumer journey," says M'lou Walker, Chief Executive Officer of LifeStyles Healthcare. "This year's survey sheds light on the evolution of the sexual wellness discourse, which increasingly becomes more dynamic via digital media. These insights will be a guiding light as we continue to innovate across the personal massager category and support comfort and confidence for all SKYN® users."
In conjunction with the survey findings, SKYN® has recently launched a new portfolio of devices that work to address the rising consumer demand for more toy options. SKYNtm Caress, Dual Ring, Tune, Arch, Bow, Wave, Rouse, Tremble, and Charm are available for purchase on the SKYN® brand website and from select retailers.
Survey Methodology The Lifestyles SKYN® Survey was conducted by Wakefield Research (www.wakefieldresearch.com) among 2,000 nationally representative U.S. adults ages 18-39, between June 23rd and July 1st, 2022, using an email invitation and an online survey. Quotas have been set to ensure reliable and accurate representation of the U.S. adult population ages 18-39.
About SKYN® by LifeStyles Healthcare Based out in Iselin, NJ, the SKYN® brand of condoms was launched by LifeStyles in 2008 as the first-ever polyisoprene, non-latex condom that met all the U.S. Food and Drug Administration requirements for safety and efficacy. The SKYN® collection is the latest extension of the LifeStyles brand portfolio, which was launched in the U.S. in 1985. SKYN® is the leading non-latex condom brand, and LifeStyles' core latex brands, such as LifeStyles, Jissbon, MANIX, Unimil and Blowtex, have 120 collective years of history, deeply rooted in each local market globally. More information on SKYN® condoms, lubricants, and devices can be found at www.SKYN.com.
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...
YOUR LEGAL RIGHTS MAY BE AFFECTED
There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...
In a landmark event signaling its ambitious foray into the biopharmaceutical sector, LOTTE BIOLOGICS, under the leadership of CEO Richard W. Lee, held a groundbreaking ceremony for its inaugural plant at the Songdo Bio Campus in Incheon International...
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematological malignancies, announced today that on July 2, 2024, in relation to...
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal...